Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2021 03; 34(3):532-541.
View in:
PubMed
subject areas
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
Biomarkers, Tumor
Biopsy
Clinical Decision-Making
Clinical Trials, Phase III as Topic
Decision Support Techniques
Disease Progression
Head and Neck Neoplasms
Humans
Immunohistochemistry
Predictive Value of Tests
Randomized Controlled Trials as Topic
Retrospective Studies
Time Factors
authors with profiles
Ezra Cohen